The use of CD137 agonist mAb urelumab also enhanced cetuximab (anti-EGFR)-activated NK-cell survival, DC maturation, and tumour antigen cross-presentation in patients with head and neck cancer. This evidence concerns the gene EGFR and neoplasm.